In just a few years, CRISPR, the revolutionary gene editing technology, has become science’s “it” discipline, giving birth to a bitter patent dispute, billions in biotech investments, and an in-development primetime TV drama. But unlike the comparatively less buzzy pursuits of virology and animal husbandry, CRISPR has lacked one of academia’s unsexier badges of honor: a peer-reviewed journal to call its own.

That’s going to change come 2018 with the arrival of The CRISPR Journal, a bimonthly publication that seeks to chronicle every breakthrough, ethical debate, and legal quandary in the world of gene editing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy